A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients.
Saved in:
| Title: | A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. |
|---|---|
| Authors: | García-Torralba E; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Navarro Manzano E; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Luengo-Gil G; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., De la Morena Barrio P; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Chaves Benito A; Department of Pathology, University Hospital Morales Meseguer, Murcia, Spain., Pérez-Ramos M; Department of Pathology, University Hospital Morales Meseguer, Murcia, Spain., Álvarez-Abril B; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Ivars Rubio A; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., García-Garre E; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Ayala de la Peña F; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., García-Martínez E; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.; Medical School, Catholic University of Murcia, Murcia, Spain. |
| Source: | Frontiers in oncology [Front Oncol] 2023 May 29; Vol. 13, pp. 1182725. Date of Electronic Publication: 2023 May 29 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37313470 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22García-Torralba+E%22">García-Torralba E</searchLink>; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22Navarro+Manzano+E%22">Navarro Manzano E</searchLink>; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22Luengo-Gil+G%22">Luengo-Gil G</searchLink>; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22De+la+Morena+Barrio+P%22">De la Morena Barrio P</searchLink>; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22Chaves+Benito+A%22">Chaves Benito A</searchLink>; Department of Pathology, University Hospital Morales Meseguer, Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22Pérez-Ramos+M%22">Pérez-Ramos M</searchLink>; Department of Pathology, University Hospital Morales Meseguer, Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22Álvarez-Abril+B%22">Álvarez-Abril B</searchLink>; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22Ivars+Rubio+A%22">Ivars Rubio A</searchLink>; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22García-Garre+E%22">García-Garre E</searchLink>; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22Ayala+de+la+Peña+F%22">Ayala de la Peña F</searchLink>; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.<br /><searchLink fieldCode="AU" term="%22García-Martínez+E%22">García-Martínez E</searchLink>; Department of Haematology and Medical Oncology, University Hospital Morales Meseguer, Murcia, Spain.; Department of Medicine, Medical School, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.; Medical School, Catholic University of Murcia, Murcia, Spain. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2023 May 29; Vol. 13, pp. 1182725. <i>Date of Electronic Publication: </i>2023 May 29 (<i>Print Publication: </i>2023). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37313470 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fonc.2023.1182725 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1182725 Titles: – TitleFull: A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: García-Torralba E – PersonEntity: Name: NameFull: Navarro Manzano E – PersonEntity: Name: NameFull: Luengo-Gil G – PersonEntity: Name: NameFull: De la Morena Barrio P – PersonEntity: Name: NameFull: Chaves Benito A – PersonEntity: Name: NameFull: Pérez-Ramos M – PersonEntity: Name: NameFull: Álvarez-Abril B – PersonEntity: Name: NameFull: Ivars Rubio A – PersonEntity: Name: NameFull: García-Garre E – PersonEntity: Name: NameFull: Ayala de la Peña F – PersonEntity: Name: NameFull: García-Martínez E IsPartOfRelationships: – BibEntity: Dates: – D: 29 M: 05 Text: 2023 May 29 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 2234-943X Numbering: – Type: volume Value: 13 Titles: – TitleFull: Frontiers in oncology Type: main |
| ResultId | 1 |
